company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,66865000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,66865000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,66865000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3059000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13088000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16147000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,50718000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,956000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-956000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,49762000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,49762000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,49762000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-2319000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,52081000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1355934.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.71
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1985644.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.67
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,30500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q2,2012-04-01,2012-06-30,2013-08-14 17:29:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.71
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,738000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,738000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,738000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2879000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9954000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12833000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12095000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-607000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,607000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11488000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11488000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11488000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,11488000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22976000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1370190.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-8.38
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1370190.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-8.38
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,2700000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2012.0,Q3,2012-07-01,2012-09-30,2013-11-06 17:23:43+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-8.38
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3108000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3108000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3108000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3039000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17722000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20761000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17653000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,489000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-489000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18142000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18142000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18142000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18142000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1400000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-12.94
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1400000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-12.94
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1401677.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q1,2013-01-01,2013-03-31,2014-05-12 18:46:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-12.94
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2601000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2601000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2601000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3708000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,20833000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24541000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21940000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-342000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,342000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21598000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21598000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21598000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,21598000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-43196000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,14681570.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.47
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,14681570.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.47
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29400000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q2,2013-04-01,2013-06-30,2013-08-14 17:29:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.47
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2766000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2766000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2766000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3907000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18088000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21995000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19229000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19229000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,679000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-18550000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-18550000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-18550000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.53
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.53
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35200761.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q3,2013-07-01,2013-09-30,2014-11-10 17:10:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.53
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2056000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2056000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2056000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4769000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22643000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27412000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25356000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-147000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,826000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,973000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24383000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-679000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-25062000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-25062000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-21598000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3464000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,22800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,11.29
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,11.29
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,22842443.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,11.29
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2372000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2372000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2372000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5241000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28155000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33396000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-31024000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-31024000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,298000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30726000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30726000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30726000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.75
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.75
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41001623.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q1,2014-01-01,2014-03-31,2015-05-06 18:55:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.75
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2415000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2415000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2415000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4937000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,28983000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33920000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-31505000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-31505000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,155000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-31350000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-31350000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-31350000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41300000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.76
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41300000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.76
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41228885.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 18:35:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.76
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2427000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2427000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2427000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6424000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,31780000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38204000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35777000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-35777000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-16000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35793000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35793000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-35793000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41600000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.86
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41600000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.86
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41402037.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 16:33:35+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.86
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2411000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2411000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2411000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6950000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,34721000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41671000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-39260000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-39260000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,4000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-39256000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-39256000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-39256000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42977463.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.82
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42977463.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.82
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.82
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2359000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2359000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2359000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9005000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,39858000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,48863000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-46504000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-46504000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-409000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-46913000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-46913000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-46913000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,49400000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.95
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,49400000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.95
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49527850.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 21:30:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.95
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2385000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2385000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2385000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8912000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,52300000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,61212000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-58827000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-58827000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,498000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-58329000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-58329000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-58329000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52100000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.12
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52100000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.12
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52147146.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q2,2015-04-01,2015-06-30,2016-08-09 16:38:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.12
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2912000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2912000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2912000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10071000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,48405000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58476000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-55564000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-55564000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,406000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-55158000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-55158000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-55158000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.05
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.05
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52576005.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q3,2015-07-01,2015-09-30,2016-11-07 17:20:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.05
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4414000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4414000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4414000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10881000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,59813000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,70694000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-66280000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,305000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,305000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-65975000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-365000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-495000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-66105000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-66105000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-66105000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.24
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.24
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51981463.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.24
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8258000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8258000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8258000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14751000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,58813000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,73564000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-65306000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-65306000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,332000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-64974000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-64974000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-64974000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.15
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.15
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,56397881.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q1,2016-01-01,2016-03-31,2016-05-05 21:30:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.15
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4231000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4231000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4231000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17044000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,44823000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,61867000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-57636000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-57636000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,297000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-57339000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-57339000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-57339000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56200000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.02
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56200000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.02
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,56399535.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q2,2016-04-01,2016-06-30,2017-08-09 16:47:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.02
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9322000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9322000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9322000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13556000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,87209000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,100765000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-91443000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-91443000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,407000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-91036000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-91036000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,1853000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-92889000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56600000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.64
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56600000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.64
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,56508426.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 20:52:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.64
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13693000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13693000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13693000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12884000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,56009000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,68893000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-55200000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,61000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1533000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1472000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-53728000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-1036000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-54764000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-54764000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-923000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-53841000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.95
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.95
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,56480647.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.95
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5128000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5128000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5128000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,15021000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,30645000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,45666000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-40538000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1639000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1639000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-42177000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,413000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-41764000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-41764000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-45000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-41719000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,56400000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.74
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,56400000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.74
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,56692788.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:45:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.74
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3787000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3787000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3787000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20329000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,49292000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,69621000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-65834000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3456000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3456000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-69290000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-124000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-69414000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-69414000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,240000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-69654000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,57100000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.22
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,57100000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.22
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,57050523.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:02:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.22
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3828000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3828000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,155000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,155000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3673000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28856000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,55273000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,84129000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-80456000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3148000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3148000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-83604000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,663000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-82941000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-82941000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-5000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-82936000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.41
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.41
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,58940764.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 16:40:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.41
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9803000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9803000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,260000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,260000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9543000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26903000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,68491000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,95394000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-85851000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3360000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1338000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4698000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-90549000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-952000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-91501000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-91501000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,280000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-91781000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,59500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.44
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,59500000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.44
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,59508156.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.44
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6644000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6644000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,336000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,336000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6308000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31541000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,60067000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,91608000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-85300000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2581000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2581000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-87881000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,3371000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-84510000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-84510000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-332000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-84178000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,65800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.28
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,65800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.28
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,65509945.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q1,2018-01-01,2018-03-31,2019-05-08 08:36:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.28
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4011000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4011000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1052000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1052000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2959000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40214000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,66440000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,106654000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-103695000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,4104000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4104000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-107799000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1828000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-105971000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-105971000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,223000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-106194000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,66000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.61
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,66000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.61
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,65884767.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:02:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.61
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14177000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14177000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4292000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4292000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9885000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,38792000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,40237000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,79029000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-69144000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,5957000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5957000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-75101000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,3924000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-71177000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-71177000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,126000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-71303000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,66000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.08
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,66000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.08
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,66165104.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q3,2018-07-01,2018-09-30,2019-11-05 17:10:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.08
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15298000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15298000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,12401000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,12401000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2897000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,40617000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,49461000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,90078000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-87181000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6098000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,13516000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,7418000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-79763000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-9123000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-88886000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-88886000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-338000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-88548000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,66000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.34
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,66000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.34
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,66017330.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.34
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22169000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22169000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,7150000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,7150000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15019000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,53034000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,35584000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,88618000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-73599000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6481000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-6481000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-80080000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1984000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-78096000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-78096000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,60000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-78156000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,66800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.17
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,66800000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.17
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,67070168.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q1,2019-01-01,2019-03-31,2020-05-11 16:10:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.17
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,28424000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,28424000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4991000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4991000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,23433000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,53855000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,33538000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,87393000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-63960000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8538000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-8538000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-72498000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,4021000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-68477000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-68477000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-2273000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-66204000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68300000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.97
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68300000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.97
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,68128238.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q2,2019-04-01,2019-06-30,2019-08-07 16:30:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.97
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,36799000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,36799000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2684000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2684000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,34115000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,52050000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25647000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,77697000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-43582000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7998000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-7998000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-51580000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,1953000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-49627000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-49627000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-49627000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,73000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.68
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,73000000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.68
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,73017609.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q3,2019-07-01,2019-09-30,2019-11-05 17:10:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.68
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,29248000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29248000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,29553000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,29553000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-305000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,59980000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,29858000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,89838000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-90143000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8273000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,9698000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1425000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-88718000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-7958000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-96676000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-96676000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-96676000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,71600000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.24
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,71600000.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.24
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71555220.0
Portola Pharmaceuticals Inc,PTLA,549300BM3O4O0CNBGJ64,0001269021,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.24
